Børge Sørvoll
Finanzdirektor/CFO bei ARCTICZYMES TECHNOLOGIES ASA
Vermögen: 223 185 $ am 30.04.2024
Aktive Positionen von Børge Sørvoll
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ARCTICZYMES TECHNOLOGIES ASA | Finanzdirektor/CFO | 01.10.2014 | - |
| Investor Relations Kontakt | 01.10.2014 | - | |
Biotec BetaGlucans AS
 Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | Vorsitzender | - | - |
Karriereverlauf von Børge Sørvoll
Ehemalige bekannte Positionen von Børge Sørvoll
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Front Exploration AS
 Front Exploration AS Contract DrillingIndustrial Services Front Exploration AS explores oil and gas and is ultimately controlled by the Government of Denmark. The company is based in Tromsø, Norway. Front Exploration was acquired by Ørsted A/S on June 27, 2012. | Finanzdirektor/CFO | - | - |
Subsea 7 Norway AS
 Subsea 7 Norway AS Miscellaneous Commercial ServicesCommercial Services Part of Subsea 7 SA, Subsea 7 Norway AS is a Norwegian company that engages in general trading activities. The company is based in Stavanger, Norway. The CEOs are John Evans, Monica Th. Bjørkmann. The company was founded in 1985. | Corporate Officer/Principal | - | - |
| Troms Kraft Invest AS | Vorstandsvorsitzender | - | - |
| Finanzdirektor/CFO | - | - |
Ausbildung von Børge Sørvoll
| University of Wyoming | Masters Business Admin |
Statistik
International
| Norwegen | 6 |
| Vereinigte Staaten | 2 |
Operativ
| Director of Finance/CFO | 3 |
| Investor Relations Contact | 1 |
| Masters Business Admin | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 2 |
| Industrial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ARCTICZYMES TECHNOLOGIES ASA | Health Technology |
| Private Unternehmen | 4 |
|---|---|
| Troms Kraft Invest AS | |
Front Exploration AS
Front Exploration AS Contract DrillingIndustrial Services Front Exploration AS explores oil and gas and is ultimately controlled by the Government of Denmark. The company is based in Tromsø, Norway. Front Exploration was acquired by Ørsted A/S on June 27, 2012. | Industrial Services |
Subsea 7 Norway AS
Subsea 7 Norway AS Miscellaneous Commercial ServicesCommercial Services Part of Subsea 7 SA, Subsea 7 Norway AS is a Norwegian company that engages in general trading activities. The company is based in Stavanger, Norway. The CEOs are John Evans, Monica Th. Bjørkmann. The company was founded in 1985. | Commercial Services |
Biotec BetaGlucans AS
Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | Health Technology |
- Börse
- Insiders
- Børge Sørvoll
- Erfahrung
